ArticleAnnals of clinical microbiology and antimicrobials2007
Factors affecting antimicrobial activity of MUC7 12-mer, a human salivary mucin-derived peptide.
Article in Annals of clinical microbiology and antimicrobials, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Natural and induced immune responses in oral cavity and saliva.BMC immunology · 2025Review
- Antifungal peptides from living organisms.Frontiers in microbiology · 2024Review
- Antimicrobial Peptide-Peptoid Hybrids with and without Membrane Disruption.ACS infectious diseases · 2023Article
- FightingInternational journal of molecular sciences · 2023Article
- Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically ImportantPharmaceutics · 2023Review
- Chimeric Peptides Derived from Bovine Lactoferricin and Buforin II: Antifungal Activity against Reference Strains and Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2022Article
- The Potential Antimicrobial Action of Human Mucin 7 15-Mer Peptide and Its Metal Complexes.International journal of molecular sciences · 2021Article
- Morphogenetic (Mucin Expression) as Well as Potential Anti-Corona Viral Activity of the Marine Secondary Metabolite Polyphosphate on A549 Cells.Marine drugs · 2020Article
- Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.Frontiers in cellular and infection microbiology · 2020Review
- Mucus and Mucins: do they have a role in the inhibition of the human immunodeficiency virus?Virology journal · 2017Review
- Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds.Journal of fungi (Basel, Switzerland) · 2017Review
- Investigation of the N-terminal coding region ofBalkan journal of medical genetics : BJMG · 2016Article
- Effects of soybean milk, chitosan, and anti-Streptococcus mutans IgY in malnourished rats' dental biofilm and the IgY persistency in saliva.Interventional medicine & applied science · 2015Article
- Insights into the antimicrobial properties of hepcidins: advantages and drawbacks as potential therapeutic agents.Molecules (Basel, Switzerland) · 2015Review
- Antifungal Activity of the Noncytotoxic Human Peptide Hepcidin 20 against Fluconazole-Resistant Candida glabrata in Human Vaginal Fluid.Antimicrobial agents and chemotherapy · 2013Article
- pH Dependence of microbe sterilization by cationic antimicrobial peptides.Antimicrobial agents and chemotherapy · 2013Article
- Article
- Antimicrobial peptide MUC7 12-mer activates the calcium/calcineurin pathway in Candida albicans.FEMS yeast research · 2010Article
- Exploring the mode of action of antimicrobial peptide MUC7 12-mer by fitness profiling of Saccharomyces cerevisiae genomewide mutant collection.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMUC7 12-mer (RKSYKCLHKRCR), a cationic antimicrobial peptide derived from the human low-molecular-weight salivary mucin MUC7, possesses potent antimicrobial activity in vitro. In order to evaluate the potential therapeutic application of the MUC7 12-mer, we examined the effects of mono- and divalent cations, EDTA, pH, and temperature on its antimicrobial activity.
methodsMinimal Inhibitory Concentrations (MICs) were determined using a liquid growth inhibition assay in 96-well microtiter plates. MUC7 12-mer was added at concentrations of 1.56-50 microM. MICs were determined at three endpoints: MIC-0, MIC-1, and MIC-2 (the lowest drug concentration showing 10%, 25% and 50% of growth, respectively). To examine the effect of salts or EDTA, a checkerboard microdilution technique was used. Fractional inhibitory concentration index (FICi) was calculated on the basis of MIC-0. The viability of microbial cells treated with MUC7 12-mer in the presence of sodium or potassium was also determined by killing assay or flow cytometry.
resultsThe MICs of MUC7 12-mer against organisms tested ranged from 6.25-50 microM. For C. albicans, antagonism (FICi 4.5) was observed for the combination of MUC7 12-mer and calcium; however, there was synergism (FICi 0.22) between MUC7 12-mer and EDTA, and the synergism was retained in the presence of calcium at its physiological concentration (1-2 mM). No antagonism but additivity or indifference (FICi 0.55-2.5) was observed for the combination of MUC7 12-mer and each K+, Na+, Mg2+, or Zn2+. MUC7 12-mer peptide (at 25 microM) also exerted killing activity in the presence of NaCl, (up to 25 mM for C. albicans and up to 150 mM for E. coli, a physiological concentration of sodium in the oral cavity and serum, respectively) and retained candidacidal activity in the presence of KCl (up to 40 mM). The peptide exhibited higher inhibitory activity against C. albicans at pH 7, 8, and 9 than at pH 5 and 6, and temperature up to 60 degrees C did not affect the activity.
conclusionMUC7 12-mer peptide is effective anticandidal agent at physiological concentrations of variety of ions in the oral cavity. These results suggest that, especially in combination with EDTA, it could potentially be applied as an alternative therapeutic agent for the treatment of human oral candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.